[Expectations in the clinical application of human-recombinant cytokines. 4) Interleukin-3 and colony-stimulation factors].
Takaku
F
F
D000380:Agranulocytosis / Q000097:blood / Q000209:etiology / Q000628:therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D001772:Blood Cell Count; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000627:therapeutic use*; D006801:Humans; D007377:Interleukin-3 / Q000627:therapeutic use*; D051379:Mice; D009369:Neoplasms / Q000150:complications; D011995:Recombination, Genetic
D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors; D006133:Growth Substances; D007377:Interleukin-3; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor